Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
Onyx Pharmaceuticals
A biopharmaceutical company developing and commercializing therapies for the treatment of cancer
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Organization
Company
Acquisition Transaction
Acquisition of Onyx Pharmaceuticals by Amgen
Acquirer
Amgen
0
AngelList URL
angel.co/onyx-pharmaceuticals
B2X
B2B
Board of Directors
Thomas G. Wiggans
0
Bill Ringo
0
CAGE Code
6SK83
0
CEO
N. Anthony Coles
0
CIK Number
1,012,140
0
Legal Name
Onyx Pharmaceuticals, Inc.
Company Operating Status
Active
Country
United States
0
Crunchbase URL
crunchbase.com/organiz...euticals
DUNS Number
789591724
0
Fax Number
650.266.0100
0
Founded Date
1991
0
Full Address
249 E. Grand Avenue South San Francisco, CA 94080
0
Headquarters
South San Francisco, California
0
Industry
Internal medicine
Medicine
Artificial Intelligence (AI)
Fitness
Healthcare
Infectious disease (medical specialty)
Biotechnology
Biology
Virology
Technology
Investors
Ridgeback Capital
IRS Number
943,154,463
0
Legal Entity Identifier
549300K47GO90N8J4853
0
LinkedIn URL
@company/onyx-pharmaceuticals
Location
South San Francisco, California
0
San Francisco
Number of Employees (Ranges)
501 – 1,000
0
Patents Assigned (Count)
1
Phone Number
+16502660000
0
Place of Incorporation
Delaware
0
SIC Code
2,836
0
Exchange
Nasdaq
Stock Symbol
ONXX
0
Twitter URL
@onyxpharmaceut
Official Website
onyx-pharm.com
Wellfound ID
onyx-pharmaceuticals
Wikidata ID
Q7095196
Find more companies like Onyx Pharmaceuticals
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE